RxDoctor Payments Data

Charles Ray, MD

Internal Medicine · Jennings, LANPI 1487732525

Payments from drug & device makers

$602in general payments, 2019–2025

Across 24 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$194
  • Novartis$70
  • Pfizer$50
  • Acadia Pharmaceuticals Inc$48
  • Vivus LLC$44
  • Ferring Pharmaceuticals Inc.$42
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$602 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$281,046
Medicare patients
206
Services billed
2,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$113,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$78,220
TrulicityDulaglutide53$64,452
XareltoRivaroxaban145$57,034
EliquisApixaban152$52,373
JanuviaSitagliptin Phosphate107$48,064
OzempicSemaglutide41$47,091
FarxigaDapagliflozin Propanediol60$34,899
RybelsusSemaglutide26$26,889
LinzessLinaclotide24$24,728
MyrbetriqMirabegron80$19,599
TradjentaLinagliptin31$15,675
JardianceEmpagliflozin28$15,430
Breo ElliptaFluticasone/Vilanterol13$9,311
Tresiba Flextouch U-200Insulin Degludec14$7,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$15$87,531113 claims
Johnson & JohnsonXarelto$12$57,034145 claims
PfizerEliquis$50$52,373152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Jennings

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →